Objectives: The purpose of this systematic review was to assess the efficacy of growth hormone (GH) treatment in patients with short bowel syndrome (SBS).
INTRODUCTION
Short bowel syndrome (SBS) is characterized by the inability to maintain protein energy, fluid, electrolyte, or micronutrient balances when on a conventionally accepted, normal diet. SBS results in chronic diarrhea, dehydration, fluid and electrolyte imbalances, and malnutrition. 1 Patients with SBS often require long-term parenteral nutrition (PN) to maintain daily nutritional requirements until the residual intestine undergoes adaptation and nutritional autonomy is obtained. However, the use of long-term PN is expensive and associated with certain complications, including venous occlusions, catheter sepsis, and liver failure. [2] [3] [4] [5] Although intestinal transplantation is the ideal option for patients with SBS, this surgery presents several problems. The long-term survival rate of intestinal transplantation is not high enough to be accepted as a routine procedure for clinical therapy. Since a program of intestinal rehabilitation, which included growth hormone (GH), glutamine, and a modified diet, was proposed by Byrne et al 6 to enhance intestinal compensation and attenuate intestinal failure, several clinical trials have been performed, with controversial results. [7] [8] [9] [10] [11] [12] [13] Some observers suggested that patients who depended on PN could be weaned after bowel rehabilitation therapy, whereas others asserted that data were inconclusive and that more trials were warranted.
To assess the efficacy and safety of GH in patients with SBS, a system review was performed with meta-analysis of relevant randomized controlled trials (RCTs).
METHODS Search Strategy
The study was conducted with a specified search strategy and eligibility criteria. An extensive electronic search of PubMed (1966 to April 30, 2010), the Science Citation Index (1900 to April 30, 2010), and the Cochrane Central Register of Controlled Trials (to The Cochrane Library Issue 4, 2010) was performed to identify relevant RCTs for the meta-analysis. Searches were limited to published English language articles. Search term combinations were "growth hormone" and "short bowel syndrome." All reference lists from the relevant articles and reviews were searched for additional relevant studies. Unavailable articles were requested from the authors.
Inclusion and Exclusion Criteria
Two reviewers independently searched the literature for relevant clinical RCTs that included patients of all ages diagnosed with SBS (defined as "a condition of malabsorption and malnutrition resulting from the loss of absorptive surface area following massive small bowel resection"). 1 Trials were eligible if they reported specific data on changes in body weight, lean body mass, intestinal absorption function (energy, nitrogen, fat, and carbohydrate), and adverse effects. Reviewers assessed method of randomization, allocation concealment, patient demographic characteristics, blinding of participants and outcome assessors, intention-to-treat analysis, interventions, number of patients lost to follow up, trial outcomes, and whether follow-up evaluations were conducted for methodological and trial design quality. Both blinded and open-design trials were eligible.
Reviews, case reports, experimental studies, unpublished data, articles not available for review, and results from non-RCTs were excluded from consideration.
Trial assessment discrepancies between the reviewers were resolved by consensus or third-party intervention.
Statistical Analysis
Statistical analysis was performed using RevMan 5 software (Cochrane IMS, Oxford, United Kingdom). Follmann's method was used for crossover studies. A correlation coefficient of 0.4 was used to calculate the standard error (SE) of the mean difference (MD). The quantities of the MD and the SE of the MD were then entered into RevMan and analyzed using a generic inverse variance outcome. Heterogeneity between trial results was tested using a standard 2 test. A fixed-effect approach was used unless there was substantial heterogeneity, in which case a random effects approach was used and the potential causes of heterogeneity examined.
RESULTS

Study Characteristics
We identified 233 reports through database searches, all of which were published and available via the Internet. Of these, 225 were rejected after review of the abstracts indicated that they were not RCTs or that they tested an intervention other than GH. Finally, 8 reports were assessed in full text; 7 were preliminarily included and 1 trial 6 was excluded because of it nonrandomized design. Of the remaining 7 reports, 2 7, 11 were excluded for lack of detailed data on results and 1 13 was rejected as a secondary publication reporting revised outcomes of a previous study. 12 Four relevant studies were finally identified, involving a total of 70 participants (Figure 1 ) 8 -10,12 All trial results were published between 1997 and 2005. Table I presents the demographic characteristics of the trial participants and interventions of RCTs included in the meta-analysis. All studies enrolled were double-blind placebo-controlled trials. The dose of GH used in these trials ranged from 0.05 to 0.14 mg/kg/d. The duration of treatment in 2 trials (low-dose GH alone, 0.05 mg/kg/d) was 3 and 8 weeks, respectively. 8, 10 The duration of treatment in 2 other trials (high-dose GH, 0.1 and 0.14 mg/kg/d, respectively, plus other treatment with oral glutamine and/or modified diet) was 4 weeks. 9, 12 Only 1 trial conducted a 12-week follow-up study, which included physical examination, nutritional history, and blood studies 9 ; no one was lost to follow up. There were no deaths in any trial.
Quality Assessment
Based on current standards, the methodological quality of all included trials was suboptimal. Allocation concealment was adequately described in all results. Although all trials used the random method, only 1 trial allocated patients by random number 10 ; 3 other trials did not identify the method of randomization. The possibility of selection bias and performance bias, therefore, could not be excluded. All trials were double-blinded, and 1 9 reported an intention-to-treat analysis.
Analysis of the Efficacy and Tolerability of Treatment
Body Weight
In their study of GH to treat SBS, Byrne et al 9 found that body weight increased from pretreatment (screening) to end of treatment and decreased at the end of follow up, but there was no clear difference between treatment groups. Further, the average body weights for groups remained within 3% of ideal body weight at the end of follow up. 9 The data were pooled from 3 crossover trials for the purpose of metaanalysis. 8, 10, 12 The results showed that GH, with or without glutamine, improved body weight significantly at the end of treatment (MD ϭ 1.66; 95% CI, 0.69 -2.63; P Ͻ 0.001) (Figure 2 ) in adults patients with SBS.
Lean Body Mass
Pooled estimates were calculated for 3 studies, 8, 10, 12 and results revealed that GH, with or without glutamine, significantly improved lean body mass at the end of treatment (MD ϭ 1.93; 95% CI, 0.97-2.90; P Ͻ 0.001) (Figure 3 ) in adult patients with SBS.
Absorption Function Assessment
The meta-analysis results showed that low-dose GH had a positive effect on intestinal absorption, whereas high-dose GH did not improve intestinal absorption. The pooled analysis showed a statistically significant effect of the treatment on increasing energy absorption (MD ϭ 4.42; 95% CI, 0.26 -8.58; P ϭ 0.04) (Figure  4) , nitrogen absorption (MD ϭ 4.85; 95% CI, 0.20 -9.49; P ϭ 0.04) (Figure 5) , and fat absorption (MD ϭ 5.02; 95% CI, 0.21-9.82; P ϭ 0.04) (Figure 6 ). However, (Figure 7) .
Adverse Effects and Mortality Assessment
Adverse effects were reported in all trials. Peripheral edema was reported in 2 trials, 9, 12 with an overall frequency of 90%. Muscle discomfort was reported in 3 studies, 8 -10 with an overall frequency of 31.48%. Arthralgic discomfort was reported in 3 studies, 8 -10 with a total occurrence probability of 33.33%. Other, minor, complications included gastrointestinal discomfort, transient gynecomastia, and nightmares. With discontinuation of GH, symptoms related to the drug resolved in all patients. There were no deaths in any trial, and quality of life was not assessed in this review.
DISCUSSION
Post-resection intestinal adaptation is complex and influenced by several factors, and management of patients with SBS is challenging and requires vigorous attention to every detail. Several trophic factors, such as GH and glutamine, that can promote adaptation of the remnant intestine have been identified in a number of animal experiments and clinical trials. GH is a protein-based peptide hormone that promotes somatic growth, stimulates protein synthesis, and regulates carbohydrate and lipid metabolism. In rodent systems, GH administration resulted in an increase in small bowel length and function per unit length.
14 Moreover, the exogenous administration of GH was reported to have positive effects on mucosal growth and intestinal adaptation after massive resection in animals. 15 In addition, insulin-like growth factor-1, which is regulated by GH, was shown to enhance intestinal hyperplasia and hypertrophy in rats after massive intestinal resection. 16 Additionally, exogenous GH had a positive effect on transport velocity of amino acids in ileum and duodenal crypt cell proliferation of cultured human explants in humans. 17 Glutamine is the primary fuel source for enterocytes. Supplemental glutamine was shown to enhance the absorption of sodium and glucose and to prevent intestinal atrophy in humans who received PN therapy. 19, 20 Glutamine is also necessary for cell signaling pathways when enterocytes are exposed to trophic factors. 21 In addition, GH has a synergistic effect on bowel uptake of glutamine. 22 The combination of GH and glutamine, therefore, might have a positive effect on bowel morphology and function.
The use of GH in human clinical studies has been widely investigated, but the effect of the treatment on intestinal adaptation in patients with SBS is still debated. [7] [8] [9] [10] In this systematic review, 4 RCTs on the efficacy and tolerability of GH, with or without glutamine, in patients with SBS, were evaluated. The results of the meta-analysis demonstrated an increase in weight, lean body mass, and absorptive capacities at the end of therapy in these patients. In this review, quality of life and nutritional status of patients with SBS at the end of follow up (at least 3 months) were the primary indexes of long-term curative effects. However, only 1 trial conducted a 12-week follow-up study. The results showed a sustained reduction in PN volume, calories, and number of infusions at the end of follow-up in patients who received GH, glutamine, and diet manipulation, whereas body weight decreased from pretreatment screening to end of follow-up. Although administration of GH might provide benefit in terms of weight gain and intestinal absorption at the end of therapy, long-term efficacy of GH has not yet been determined.
Adverse effects were reported in all trials in this review. Fluid retention was the major side effect of GH administration and was reported in 2 trials using high-dose GH, 9, 12 although fluid retention did not occur and only minor side effects were reported in the 2 trials using low-dose GH. 8, 10 Symptoms related to GH resolved in all patients at discontinuation of GH. Findings from the meta-analysis suggested that low-dose GH was more tolerable than high-dose GH.
In addition, there was a high degree of statistical heterogeneity among the study results investigated in the meta-analysis. There were several reasons for the inconsistent results, such as variation in patient selection, drug dosage, use of glutamine, length of study, and method of assessing outcome.
In contrast to a previous meta-analysis, 23 we examined 4 well-designed RCTs that focused on the efficacy and safety of GH for patients with SBS. Although administration of GH might provide benefit in terms of weight gain and intestinal absorption at the end of therapy, the long-term efficacy of GH remains unknown. Furthermore, given the small number of patients enrolled in these studies, the present results should be interpreted with caution. Large-scale, long-term follow-up RCTs are needed to confirm the efficacy and safety of GH in the treatment of SBS.
CONCLUSION
This systematic review suggests a possible short-term benefit in terms of body weight, lean body mass and absorptive capacities. However, no conclusion of long-term efficacy of GH could be obtained as yet. Given the small number of patients enrolled in these studies, the present results should be interpreted with caution. Large-scale, long-term follow-up RCTs are needed to confirm the efficacy and safety of GH treatment in patients with SBS in the future.
